Page 14 - reflections_dyslipidaemia_newsletter9_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #9 2025

This expert clinical consensus offers evidence-based
recommendations, tailored for a growing patient population CLINICAL PEARLS FROM THE FACULTY Dyslipidaemia
where definitive trial data are still emerging. It underscores
the importance of shared decision-making, engaging patients
and their caregivers to align treatment strategies with
individual preferences, goals of care, functional status, and
life expectancy. The ongoing large-scale Statin Therapy for
Reducing Events in the Elderly (STAREE) and PRagmatic
EValuation of evENTs And Benefits of Lipid-lowering in
oldEr adults (PREVENTABLE) trials are expected to provide
definitive insights into the benefits and risks of statin initiation
in older adults, while the Statins In The Elderly (SITE) and
Statins in Multimorbid Older Adults Without Cardiovascular
Disease (STREAM) studies will further inform statin WATCH
deprescribing strategies. Ultimately, for older adults without a PROF. MARCIN WELNICKI DISCUSS
life-limiting illness, primary prevention with a statin remains a THE CLINICAL RELEVANCE OF THIS
viable strategy. ARTICLE.

CLICK HERE
FOR THE LINK TO FULL ARTICLE

ARTICLES OF INTEREST

REVIEWS

1. Apolipoprotein B-containing lipoproteins in atherogenesis. Boren J, et al. Nat Rev Cardiol. 2025 Jun; 22(6):399-413.

2. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Brinton EA, et al.
Atherosclerosis. 2025 Apr:403:119114.

3. What’s next for lipoprotein(a)? A National Lipid Association report from an expert panel discussion. Koschinsky ML,
et al. J Clin Lipidol. 2024 Nov-Dec;18(6):e886-e892.
EPIDEMIOLOGY AND GENETICS

4. Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit
from aggressive lipid lowering. Marston NA, et al. Nat Med. 2025 Mar;31(3):963-969.

5. Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease
in 13 countries across 6 WHO Regions: Results from INTERASPIRE. Santos RD, et al. Atherosclerosis. 2025
Jun:405:119215.

6. Global variation in lipoprotein(a) levels among patients with coronary heart disease: Insights from the
INTERASPIRE study and implications for emerging Lp(a)-lowering therapies. Barkas F, et al. J Am Coll Cardiol. 2025
Jun 3;85(21):2028-2042.

TABLE OF CONTENTS